Floatz logo

The-0504

Gastric Cancer (GC)

Thena Biotech S.r.l.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

282 Active assets in the Gastric Cancer (GC) cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

The-0504 is also rated in:

colorectal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →